Brokerages Set Vyome Holdings, Inc. (NASDAQ:HIND) Target Price at $15.00

Shares of Vyome Holdings, Inc. (NASDAQ:HIND) have received a consensus recommendation of “Hold” from the five ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $15.00.

A number of analysts have recently issued reports on HIND shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vyome in a research report on Wednesday, July 29th. Litchfield Hills Research began coverage on shares of Vyome in a research note on Monday, May 4th. They issued a “buy” rating on the stock. Finally, Zacks Research upgraded shares of Vyome to a “hold” rating in a research report on Wednesday, May 6th.

Institutional Trading of Vyome

A hedge fund recently bought a new position in Vyome stock. Geode Capital Management LLC acquired a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned about 0.21% of Vyome as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 22.06% of the company’s stock.

Vyome Stock Performance

NASDAQ:HIND opened at $2.28 on Friday. The firm has a market capitalization of $16.01 million, a price-to-earnings ratio of -0.68 and a beta of 1.48. Vyome has a 52-week low of $1.75 and a 52-week high of $12.00. The stock has a fifty day moving average of $2.18 and a 200 day moving average of $2.29.

Vyome (NASDAQ:HIND) last announced its earnings results on Wednesday, August 12th. The company reported ($0.10) earnings per share for the quarter. Vyome had a negative return on equity of 197.33% and a negative net margin of 3,024.84%.The business had revenue of $0.27 million during the quarter. Equities analysts forecast that Vyome will post -0.6 earnings per share for the current fiscal year.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.